Profound Medical Corp. develops and markets interventional MRI medical devices for incision-free tissue ablation. Its recurring news centers on TULSA-PRO® and the TULSA Procedure™, which use real-time MRI guidance, robotically controlled transurethral ultrasound and temperature feedback to ablate prostate tissue in prostate cancer and benign prostatic hyperplasia.
Company updates also cover Sonalleve®, an MRI-guided therapy used for pain palliation of bone metastases, desmoid tumors and osteoid osteoma, as well as gynecologic conditions including uterine fibroids and adenomyosis. Recurring developments include financial results, revenue guidance, payer coverage, CAPTAIN post-market clinical data, scientific-meeting presentations, treatment-site adoption milestones and investor conference updates.
Profound Medical (NASDAQ:PROF; TSX:PRN) entered a co-education agreement with Telix Pharmaceuticals to educate physicians on imaging-informed prostate care.
The agreement establishes a framework for education on Telix’s PSMA-PET molecular imaging and Profound’s MRI-guided TULSA-PRO prostate tissue ablation platform. Planned activities include medical meetings, speaker programs, webinars and clinical case studies. Profound says the collaboration increases its access to urologists in the U.S. and internationally and could help broaden the population considered for the TULSA Procedure.
Profound is also developing image-fusion capabilities for a planned future Treatment Delivery Console software release. The functionality is intended to combine Telix’s diagnostic imaging data with real-time MRI during treatment planning; improved patient selection and treatment outcomes remain potential benefits.
Profound Medical (NASDAQ:PROF; TSX:PRN) expects third-quarter 2026 revenue of $9.8 million to $10.0 million, based on preliminary unaudited results. For the quarter ended September 30, expected revenue growth is approximately 85% to 89% against $5.3 million a year earlier and approximately 292% to 300% against $2.5 million in the second quarter of 2026. All amounts are in U.S. dollars.
Expected revenue is approximately 45% to 47% above Bloomberg's mean analyst consensus of $6.78 million. Gross margin is expected to exceed 70% again. The company attributes the expected growth to increased commercial activity across its installed base and new customer accounts. Actual revenues may differ from these preliminary figures. Profound intends to release full quarterly results after market close on November 5, 2026.
Profound Medical (PROF) will participate in Lake Street Capital Markets’ “BIG10” 10th Annual Best Ideas Growth Conference on September 10, 2026, in New York City. Management will hold one-on-one investor meetings, and no webcast will be provided due to the event format.
Profound is a commercial-stage medical device company focused on interventional MRI (iMRI) procedures. Its flagship TULSA-PRO platform enables MRI-guided, incision-free prostate tissue ablation, supporting a range of personalized prostate cancer treatment strategies. The company also commercializes Sonalleve, an MRI-guided therapy for non-surgical treatment of pain palliation of bone metastases, desmoid tumors, osteoid osteoma, and certain gynecologic conditions such as uterine fibroids and adenomyosis.
TULSA-PRO is FDA-cleared in the United States for transurethral ultrasound ablation of prostate tissue and is also cleared in Europe, Canada, Saudi Arabia, India, Australia/New Zealand, and the UAE. Sonalleve has FDA HDE approval in the United States for osteoid osteomas in the extremities and is also cleared or approved in Europe, Canada, China, and Saudi Arabia.
Profound Medical (NASDAQ:PROF; TSX:PRN) appointed Richard (Rich) Fabian as President, effective immediately. He succeeds Mathieu Burtnyk, PhD, who moves into the newly created role of Chief Technology Officer, reflecting a leadership realignment between commercial execution and technology innovation.
Fabian brings over 29 years of global healthcare experience in medical imaging and devices, including serving as CEO of FUJIFILM Sonosite and earlier executive roles at Philips Healthcare, STERIS, and Noetix. According to Profound, Burtnyk, inventor of the patented closed-loop temperature feedback control algorithm used by TULSA-PRO and leader of all clinical study design for the technology, will continue to guide clinical innovation, including the ongoing Level 1 post-market CAPTAIN randomized controlled trial.
The company highlights its commercial-stage platforms TULSA-PRO for MRI-guided, incision-free prostate ablation and Sonalleve for non-surgical treatment of bone metastases, desmoid tumors, osteoid osteoma and gynecologic conditions, both cleared or approved in multiple major global markets.
Profound Medical (NASDAQ:PROF) announced the introduction of its latest Treatment Delivery Consol (TDC) software for the TULSA-PRO® platform, which is being deployed across the existing installed base. The upgrade builds on prior TULSA-AI® modules to enhance procedural efficiency, physician experience, and reduce planning complexity.
The new software adds real-time interventional MRI control, giving surgeons greater direct control over TULSA-PRO’s supervised robotic autonomy, along with physician-requested user interface and hardware-control improvements. According to Profound Medical, these features are intended to streamline TULSA Procedure™ workflows and provide a potential roadmap to enable surgeons to perform up to six procedures per system per day.
Profound Medical (NASDAQ:PROF; TSX:PRN) announced a management change, promoting Matthew Sobczyk from Corporate Controller to Interim Chief Financial Officer, effective immediately. Sobczyk, who joined Profound in 2020, succeeds Rashed Dewan, who has stepped down as CFO.
According to Profound Medical, Dewan will remain on a short-term consulting contract to support a smooth transition. CEO and Chairman Arun Menawat said Sobczyk’s deep knowledge of the company and financial expertise are expected to help maintain continuity and operational discipline as Profound advances adoption of its MRI-guided TULSA-PRO and Sonalleve technologies.
Profound Medical (NASDAQ:PROF) announced the launch of Let’s Huddle, a global patient community aimed at supporting men and their families throughout the prostate care journey. Led by Global Patient Ambassador Leonard Wheeler, a former NFL player and prostate cancer survivor, the initiative focuses on education, peer connection, and advocacy around prostate disease.
Let’s Huddle brings together patients, survivors, care partners, healthcare professionals, and advocates to share real patient experiences, educational resources, and survivorship support. According to Profound, the program extends its commitment beyond its MRI-guided TULSA-PRO platform by helping organizations strengthen patient education, build trust, and promote comprehensive, patient-centered prostate care worldwide.
Profound Medical (NASDAQ:PROF) reported Q2‑2026 revenue of $2.5 million, up 12% year-over-year, with $1.6 million from recurring non-capital sales and $871,000 from capital equipment. About $3.1 million of TULSA shipments slipped into July, which the company said reflected logistics timing only; excluding this, revenue would have been about $5.6 million, or 153% growth.
Gross margin rose to 78% from 73%, while operating expenses fell 16% to roughly $13.0 million, improving net loss 39% to $9.5 million ($0.26 per share). Cash was $38.3 million at June 30, 2026. The TULSA-PRO installed base reached 84, payer coverage grew by approximately 18.3 million lives, and two employer health plans added the TULSA Procedure™ as a covered service. Profound reiterated its 2026 revenue outlook of about $25.0 million, implying 56% growth, and continues to expect full-year gross margin of at least 70%.
Profound Medical (NASDAQ:PROF; TSX:PRN) reported new Level 1 post-market data from the randomized CAPTAIN trial comparing the TULSA Procedure™ with robotic radical prostatectomy in men with organ-confined, intermediate-risk Gleason 7 prostate cancer.
At 1 month, there was no median change in penile length after whole-gland TULSA, versus a median 0.65 cm reduction after robotic RP. According to Profound, a mixed-effects model showed a 0.42 cm between-arm difference (p<0.001), favoring TULSA. The company positions these results as additional quality-of-life context to previously disclosed CAPTAIN primary safety data, where TULSA demonstrated statistically significant superiority over robotic RP in preserving erectile function and urinary continence at 6 months.
CAPTAIN is a prospective, multi-center randomized trial that ultimately treated 211 patients across 23 sites. Its primary endpoints assess preservation of erectile potency and urinary continence at 1 year and cancer control outcomes at 3 years.
Profound Medical (NASDAQ:PROF; TSX:PRN) will release its second quarter 2026 financial results after market close on Thursday, August 6, 2026. Management will host a conference call at 4:30 p.m. ET the same day to review results and discuss business developments.
Investors can register for the live call via the provided online registration link, and the conference will also be broadcast live and subsequently archived in the Investors section of the company’s website.